Arimidex Powder Raws

State: Solid
Purity: >99%
Formula: C17H19N5
CAS Number: 120511-73-1
Appearance: White Powder
Molar Mass: 293.366 g/mol
Policy: Free Reship Policy
Suitable for: Elderly, Adult
Certification: GMP, ISO 9001, USP
Usage: in Building Muscle, Burning Fat, etc

What is Arimidex?

Arimidex is one of the most welcome PCT products. As an aromatase inhibitor, Arimidex's mechanism of action - blocking conversion of aromatizable steroids to estrogen - is in contrast to the mechanism of action of anti-estrogens such as clomiphene (Clomid) or tamoxifen (Nolvadex), which block estrogen receptors in some tissues, and activate estrogen receptors in others. During a cycle, if using Arimidex, there is generally no need to use Clomid as well, but (as mentioned in the section on Clomid) there may still be benefits to doing so.

Arimidex Functions

Arimidex belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of antineoplastics known as non-steroidal aromatase inhibitors. It fights breast cancer by inactivating an enzyme known as aromatase. This prevents the enzyme from supplying the estrogen that allows certain types of breast cancers to grow.
It lowers the amount of oestrogen in the body. The female sex hormones oestrogen and progesterone stimulate many breast cancers to grow. Lowering the level of oestrogen can stop or slow the growth of breast cancer cells. Arimidex blocks a process called aromatisation that changes sex hormones called androgens into oestrogen. This happens mainly in the fatty tissues, muscle and the skin and needs a particular enzyme called aromatase.

Approved Uses for Arimidex

Arimidex is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer.
Arimidex is approved for the initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. Patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to Arimidex.

Arimidex COA

Important Information You Should Make Clear Before Taking Arimidex

1.Prescription Arimidex is only for postmenopausal women. Arimidex should not be taken if you are pregnant because it may harm your unborn child. Do not take Arimidex if you are allergic to any of its ingredients.
2.Based on information from a study in patients with early breast cancer, women with a history of blockages in heart arteries (ischemic heart disease) who take Arimidex may have a slight increase in this type of heart disease compared to similar patients who take tamoxifen
3.Arimidex can cause bone softening/weakening (osteoporosis) increasing the chance of fractures. In a clinical study in early breast cancer, there were more fractures (including fractures of the spine, hip, and wrist) with Arimidex (10%) than with tamoxifen (7%)
4.In a clinical study in early breast cancer, some patients taking Arimidex had an increase in cholesterol. Skin reactions, allergic reactions, and changes in blood tests of liver function have also been reported
5.In the early breast cancer clinical trial, the most common side effects seen with Arimidex include hot flashes, joint symptoms (including arthritis and arthralgia), weakness, mood changes, pain, back pain, sore throat, nausea and vomiting, rash, depression, high blood pressure, osteoporosis, fractures, swelling of arms/legs, insomnia, and headache
6.In advanced breast cancer trials, the most common side effects seen with Arimidex versus tamoxifen include hot flashes, nausea, decreased energy and weakness, pain, back pain, headache, bone pain, increased cough, shortness of breath, sore throat, and swelling of arms and legs. Joint pain/stiffness has been reported in association with the use of Arimidex
7.Arimidex should not be taken with tamoxifen or estrogen-containing therapies